Pittenger & Anderson Inc’s NovoCure NVCR Stock Holding History

Pittenger & Anderson Inc’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-74	Closed	-$4.45K	–	480
2023 Q1	$4.45K	Hold	74	–	–	﹤0.01%	391
2022 Q4	$5.43K	Hold	74	–	–	﹤0.01%	369
2022 Q3	$6K	Buy	74 +14	+23%	+$1.09K	﹤0.01%	368
2022 Q2	$4K	Hold	60	–	–	﹤0.01%	391
2022 Q1	$5K	Hold	60	–	–	﹤0.01%	383
2021 Q4	$5K	Buy	60 +19	+46%	+$1.91K	﹤0.01%	397
2021 Q3	$5K	Buy	41 +6	+17%	+$907	﹤0.01%	394
2021 Q2	$8K	Buy	35 +10	+40%	+$1.95K	﹤0.01%	336
2021 Q1	$3K	Hold	25	–	–	﹤0.01%	365
2020 Q4	$4K	Hold	25	–	–	﹤0.01%	338
2020 Q3	$3K	Buy	25 +6	+32%	+$480	﹤0.01%	335
2020 Q2	$1K	Hold	19	–	–	﹤0.01%	353
2020 Q1	$1K	Buy	19 +8	+73%	+$632	﹤0.01%	346
2019 Q4	$1K	Hold	11	–	–	﹤0.01%	361
2019 Q3	$1K	Buy	+11	New	+$880	﹤0.01%	356

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Pittenger & Anderson Inc's NVCR Position: Q2 2023 in Review

Pittenger & Anderson Inc sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 74 shares — an estimated $4.45K sold.

Pittenger & Anderson Inc first reported a position in NVCR in Q3 2019 and held it in 15 quarters. The position peaked at $8K in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Pittenger & Anderson Inc reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Pittenger & Anderson Inc sold 74 NovoCure shares in Q2 2023, an estimated $4.45K.
Pittenger & Anderson Inc first reported a position in NovoCure in Q3 2019 and held it in 15 quarters.
Pittenger & Anderson Inc's NovoCure position peaked at $8K in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Pittenger & Anderson Inc's 13F filing for Q2 2023, filed 9 Aug 2023.